Infectious substance testing is a critical laboratory discipline focused on detecting, identifying, and classifying pathogenic microorganisms and contaminated materials in clinical, pharmaceutical, and environmental samples. By combining culture-based methods, molecular assays, and immunochemical techniques in accordance with ISO, WHO, and pharmacopoeial standards, accredited third-party laboratories help safeguard public health, ensure product safety, and support regulatory compliance for the transport and handling of dangerous biological goods.
Technical Overview
Infectious substances are materials known or reasonably expected to contain pathogens such as bacteria, viruses, rickettsiae, parasites, fungi, or prions. Under the United Nations Model Regulations and the WHO guidance on the transport of infectious substances, these materials are classified as Class 6.2 dangerous goods and are divided into Category A (UN 2814 for human pathogens, UN 2900 for animal pathogens) and Category B (UN 3373, biological substances). Infectious substance testing encompasses the detection, identification, enumeration, and inactivation validation of pathogenic agents across clinical, industrial, and environmental contexts.
Testing is performed under strictly controlled biosafety conditions, typically in laboratories operating at Biosafety Level 2 (BSL-2) or higher in accordance with ISO 15190 and the WHO Laboratory Biosafety Manual. Reliable results depend on validated methods, competent personnel, and rigorous quality management aligned with ISO 15189 for medical laboratories and ISO/IEC 17025 for general testing laboratories. Beyond clinical diagnosis, infectious substance testing underpins pharmaceutical quality control, medical device sterilization validation, biological product release testing, and the safe classification of specimens for air and ground transport under the IATA Dangerous Goods Regulations.
Testing Samples
Clinical and Diagnostic Specimens
Clinical specimens represent the most common category of infectious materials submitted for analysis. These include blood and blood components, serum and plasma, urine, sputum and respiratory secretions, nasopharyngeal and oropharyngeal swabs, stool samples, cerebrospinal fluid, wound exudates, and tissue biopsies. Proper collection, preservation, and transport conditions are essential to maintain microorganism viability and nucleic acid integrity prior to analysis.
Biopharmaceutical and Biological Products
Biologics, vaccines, cell and gene therapy products, blood products, and monoclonal antibodies require comprehensive microbiological and infectious agent testing prior to release. This includes sterility testing, mycoplasma detection, adventitious virus screening, and endotoxin quantification in accordance with pharmacopoeial monographs and ICH Q5A(R2) guidance on viral safety evaluation.
Medical Devices and Health Care Products
Single-use and reusable medical devices, implants, dressings, and sterilization wrappers are tested for bioburden, sterility assurance, and microbial limits. Testing supports validation of sterilization processes and conformity with ISO 11737-1 and ISO 11737-2 microbiological methods.
Environmental and Water Samples
Environmental monitoring samples include pharmaceutical cleanroom air, surface contact plates and swabs, process water, purified water systems, and wastewater. These samples are analyzed for total viable counts, objectionable organisms, and specific pathogens to verify contamination control strategies.
Veterinary, Food, and Research Materials
Animal-derived samples, food and feed matrices, and research biological materials such as cell lines, culture media, and sera are screened for zoonotic agents, spoilage organisms, and adventitious contaminants that may compromise safety or experimental integrity.
Testing Items
Infectious substance testing programs typically address the following analytical targets:
- Identification of pathogenic bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), Salmonella species, Listeria monocytogenes, Escherichia coli O157:H7, Mycobacterium tuberculosis, and Legionella species
- Detection of pathogenic viruses, including influenza viruses, coronaviruses, hepatitis B and C viruses, HIV, and emerging arboviruses, using nucleic acid and serological approaches
- Fungal and parasitic agent identification, including Candida species, Aspergillus species, and protozoan parasites
- Sterility testing of pharmaceutical products and medical devices per ISO 11737-2, USP <71>, and Ph. Eur. 2.6.1
- Bioburden determination per ISO 11737-1 and USP <61> microbial enumeration
- Bacterial endotoxin testing using Limulus Amebocyte Lysate (LAL) methods per USP <85> and ISO 10993-12 sample preparation
- Mycoplasma detection in cell banks and biological products per USP <63> and Ph. Eur. 2.6.7
- Antimicrobial susceptibility testing and resistance gene profiling
- Transport classification assessment to determine whether a substance meets Category A or Category B criteria
Testing Methods
Culture-Based and Phenotypic Methods
Classical microbiology remains foundational for viable organism detection. Techniques include enrichment culture, selective and differential plating, membrane filtration for water and large-volume samples, colony counting, Gram and acid-fast staining, and biochemical identification systems. Culture methods provide isolate viability and enable downstream antimicrobial susceptibility testing, although turnaround times may extend from two days to several weeks for slow-growing organisms.
Molecular Biology Methods
Nucleic acid amplification techniques offer high sensitivity and specificity with rapid turnaround. These include conventional PCR, real-time quantitative PCR (qPCR), reverse transcription PCR (RT-PCR) for RNA viruses, multiplex PCR panels, and isothermal amplification methods such as LAMP. Sanger sequencing of 16S rRNA and 18S rRNA genes, along with next-generation sequencing (NGS), enables unbiased pathogen discovery, strain typing, and genomic epidemiology. Molecular methods are increasingly validated against ISO 22174 general requirements for PCR foodborne pathogen detection and related ISO real-time PCR standards.
Immunological and Serological Methods
Immunoassays detect microbial antigens or host antibody responses. Common formats include enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassays (CLIA), rapid lateral-flow antigen tests, immunofluorescence assays, western blotting, and agglutination tests. These methods support seroprevalence studies, blood donor screening, and confirmation of infectious status.
Mass Spectrometry and Biochemical Identification
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) enables rapid, cost-effective identification of cultured bacteria and yeasts by protein fingerprint matching against validated reference databases, significantly reducing identification time compared with conventional biochemical panels.
Viral Infectivity and Cell-Based Assays
Quantitative infectivity methods include plaque assays, tissue culture infectious dose (TCID50) determinations, and cytopathic effect observation in susceptible cell lines. These assays are essential for vaccine potency evaluation, virus clearance validation, and disinfectant efficacy studies.
Endotoxin and Pyrogen Testing
Bacterial endotoxins are quantified using gel-clot, kinetic turbidimetric, and kinetic chromogenic LAL techniques, or the recombinant factor C (rFC) assay as a non-animal alternative, in accordance with USP <85>, Ph. Eur. 2.6.32, and ISO 10993-11 considerations for medical devices.
Applications
Infectious substance testing serves diverse sectors and regulatory objectives:
- Clinical diagnostics: pathogen identification, antimicrobial resistance surveillance, and outbreak investigation in hospitals and public health laboratories
- Pharmaceutical and biopharmaceutical quality control: sterility release testing, adventitious agent screening, and environmental monitoring of aseptic manufacturing facilities
- Medical device sterilization validation: bioburden enumeration, sterilization cycle validation using biological indicators per ISO 11138, and sterility assurance level verification
- Dangerous goods transport compliance: classification of patient specimens and cultures as Category A or Category B under UN Model Regulations and IATA requirements, including packaging validation under ISO 16104 and UN 38.2-related performance testing concepts where applicable
- Blood and tissue safety: donor screening for transfusion-transmissible agents and qualification of tissue banks
- Food and water safety: detection of foodborne pathogens and waterborne microorganisms in support of HACCP programs and drinking water regulations
- Biosafety and research integrity: contamination control for cell lines, characterization of biological reference materials, and verification of decontamination procedures
FAQ
What is the difference between Category A and Category B infectious substances?
Category A substances are pathogens that can cause permanent disability, life-threatening, or fatal disease in healthy humans or animals upon exposure, and they are assigned UN 2814 or UN 2900 with strict packaging and documentation requirements. Category B substances do not meet Category A criteria and are assigned UN 3373 as biological substances with less stringent, but still regulated, packaging requirements.
Which standards govern infectious substance testing?
Key standards include ISO 11737-1 and ISO 11737-2 for microbiological methods on health care products, ISO 15189 and ISO 15190 for medical laboratory quality and safety, ISO 35001 for biorisk management, pharmacopoeial monographs such as USP <71>, USP <85>, and Ph. Eur. 2.6.1, and the WHO Laboratory Biosafety Manual. GB national standards, including GB 19489 for laboratory biosafety, apply within their respective jurisdictions.
How long does infectious substance testing take?
Turnaround time varies by method. Rapid antigen tests and molecular assays can deliver results within hours, culture-based identification typically requires two to seven days, and sterility testing incubation generally spans fourteen days per pharmacopoeial requirements. Slow-growing organisms such as mycobacteria may require several weeks.
What biosafety measures are required during testing?
Testing is conducted in laboratories equipped with appropriate containment levels, biological safety cabinets, validated decontamination procedures, and personnel protective equipment. Risk assessments are documented in accordance with ISO 35001 and institutional biosafety committees, ensuring that manipulation of infectious materials matches the risk group of the agent involved.
Can accredited third-party laboratories perform full classification for transport purposes?
Yes, accredited third-party laboratories provide characterization data such as pathogen identification and viability assessment that inform classification decisions. Final shipping classification remains the responsibility of the shipper, supported by laboratory findings, technical instructions, and applicable UN and IATA regulatory criteria.